Ketamine

Mike Wang, Sc.M, Paul Nestadt, M.D.

Ketamine is a topic covered in the Johns Hopkins Psychiatry Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

A COVID-19 Conversation - Variants, Vaccines, and Long-Term Effects

Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 Pandemic

Moderna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

DESCRIPTION

Ketamine hydrochloride is a general anesthetic used at sub-anesthetic doses for off-label treatment of depressive symptoms. It is notable as both an unusually fast-acting antidepressant (within 4 hrs) and a psychomimetic agent (meaning that it in higher doses it can mimic psychosis). Due to ketamine’s dissociative and psychomimetic effects, its administration is done under clinical supervision. An intranasal preparation of the S enantiomer of ketamine (esketamine, brand name SPRAVATO) is FDA approved for TRD.[1][2]

-- To view the remaining sections of this topic, please log in or purchase a subscription --

DESCRIPTION

Ketamine hydrochloride is a general anesthetic used at sub-anesthetic doses for off-label treatment of depressive symptoms. It is notable as both an unusually fast-acting antidepressant (within 4 hrs) and a psychomimetic agent (meaning that it in higher doses it can mimic psychosis). Due to ketamine’s dissociative and psychomimetic effects, its administration is done under clinical supervision. An intranasal preparation of the S enantiomer of ketamine (esketamine, brand name SPRAVATO) is FDA approved for TRD.[1][2]

There's more to see -- the rest of this entry is available only to subscribers.